Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-11-26
2009-11-03
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C424S130100, C424S133100, C424S139100, C424S142100
Reexamination Certificate
active
07612179
ABSTRACT:
A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
REFERENCES:
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 6046381 (2000-04-01), Mucke et al.
patent: 6107045 (2000-08-01), Koren et al.
patent: 6787519 (2004-09-01), Huang et al.
patent: 2002/0155426 (2002-10-01), Cordell et al.
patent: 2004/0157267 (2004-08-01), Huang
patent: 1434053 (2004-06-01), None
patent: WO 94/09155 (1994-04-01), None
patent: WO 2004/011943 (2004-02-01), None
Cho et al. Journal of Neuropathology and Experimental Neurology 60(4): 342-349. Apr. 2001.
Rudikoff, S., Giusti, A.M., Cook, W.D., and Scharff, M.D. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
MacCallum, R.M., Martin, A.C.R., and Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, F.F., Adams, C.W., Breece, T.N., Presta, L.G., De Vos, A.M., and Sidhu, S.S. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, P., Jafari, R., and Sundstrom, B.E. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Wu, H., Nie, Y., Huse, W.D., and Watkins, J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H.W., McKay, P., De Vos, A.M., and Lowman, H.B. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of “abbreviated” complementarity-determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Li, Yamashiro, Tseng, Chang, and Ferrara. B-endorphin omission analogs: dissociation of immunoreactivity from other biological activites. Proceedings of the National Academy of Sciences, 1980. vol. 77, pp. 3211-3214.
Lederman, De Martino, Daugherty, Foeldvari, Yellin, Cleary, Berkowitz, Lowy, Braunstein, Mark, and Chess. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody OKT4. Molecular Immunology, 1991. vol. 28, pp. 1171-1181.
Aizawa et al. “Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brians: A possible role for apolipoprotein E in Alzheimer's disease” Brain Res. 768:208-214 (1997).
Bi et al. “Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice” Proc. Natl. Acad. Sci. USA 98:8832-8837 (2001).
Bury et al. “1. Apoliprotein quantification by ELISA: Technical aspects and clinical applications” Rev. Immuno. Technol. 1:1-25 (1998).
Carlsson et al. “Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid” Clin. Chimica Acta 196:167-176 (1991).
Castano et al. “Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L” J. Biol. Chem. 270:17610-17615 (1995).
Demeester et al. “Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: Cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease” J. Lipid Res. 41:963-974 (2000).
Golabek et al. “Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid β-peptide with the N-terminal, receptor binding domain of apolipoprotein E” Biophys. J. 79:1008-1015 (2000).
Harris et al. “Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice” Proc. Natl. Acad. Sci. USA 100:10966-10971 (2003).
Huang et al. “Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons” Proc. Natl. Acad. Sci. USA 98:8838-8843 (2001).
Klezovitch et al. “Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan” J. Biol. Chem. 275:18913-18918 (2000).
Labeur et al. “Immunological assays of apolipoproteins in plasma: Methods and instrumentation” Clin. Chem. 36:591-597 (1990).
Lee et al. “Microbial cell-surface display” Trends Biotechnol. 21:45-52 (2003).
Lynch et al. “Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response” J. Neuroimmunol. 114:107-113 (2001).
Mahley et al. “Apolipoprotein E structure, function, and possible roles in Alzheimer's disease” Ann. N.Y. Acad. Sci. 777:139-145 (1996).
Namba et al. “Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease” Brain Res. 541:163-166 (1991).
Näslund et al. “Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain” Neuron 15:219-228 (1995).
Nishida et al. “Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies” Br. J. Ophthalmol. 83:1178-1182 (1999).
Perugini et al. “Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid” J. Biol. Chem. 275:36758-36765 (2000).
Pillot et al. “β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease” J. Neurochem. 72:230-237 (1999).
Saunders et al. “The role of apolipoprotein E in Alzheimer's disease: Pharmacogenomic target selection” Biochim. Biophys. Acta 1502:85-94 (2000).
Sparrow et al. “Apolipoprotein E: Phospholipid binding studies with synthetic peptides from the carboxyl terminus” Biochem. 31:1065-1068 (1992).
Terai et al. “Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease” Brain Res. 900:48-56 (2001).
Weisgraber et al. “Human apolipoprotein E: The Alzheimer's disease connection” FASEB J. 10:1485-1494 (1996).
Wisniewski et al. “Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid” Neurosci. Lett. 135:235-238 (1992).
Wisniewski et al. “Is Alzheimer's disease an apolipoprotein E amyloidosis?” Lancet 345:956-958 (1995).
Chemicon International “Goat anti-apolipoprotein E polyclonal antibody,” Catalog No. AB947 (2001).
Chemicon International “Mouse anti-apolipoprotein E monoclonal antibody,” Catalog No. MAB1062 (2002).
Biodesign International, Catalog No. H61529M (2002).
International Search Report for PCT/EP2004/013426 dated Jun. 3, 2005.
Yamada et al., “Further characterization of a monoclonal a
Andersson Christin V.
Goldschmidt Tom
Henderikx Maria
Hoet Rene
Hoogenboom Henricus
Astrazeneca AB
Blanchard David J.
Dyax Corporation
Gussow Anne M.
Nixon & Vanderhye P.C.
LandOfFree
antibodies binding to a C-terminal fragment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with antibodies binding to a C-terminal fragment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and antibodies binding to a C-terminal fragment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079977